Clearmind Medicine (CMND) said Thursday that the Macau International Intellectual Property Office has granted a patent for its binge behavior treatment.
The patent is directed to be used a a primary amine aminoindan compound for binge behavior regulation, including such compounds beyond its psychedelic molecule, 5-methoxy-2-aminoindan.
Shares of Clearmind Medicine were up over 7% in premarket activity Thursday.
Price: 1.48, Change: +0.10, Percent Change: +7.25
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。